Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients

Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of highly active relapsing-remitting multiple sclerosis (MS). The principal adverse effect is the development of secondary autoimmune disorders during the immune reconstitution period after alemtuzumab, with autoim...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazakou, Paraskevi, Tzanetakos, Dimitrios, Vakrakou, Aigli G, Tzartos, John S, Anagnostouli, Maria, Koutsis, Georgios, Andreadou, Elisabeth, Evangelopoulos, Maria Eleptheria, Kilidireas, Constantinos, Zapanti, Evangelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089514/
http://dx.doi.org/10.1210/jendso/bvab048.1727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089514/
http://dx.doi.org/10.1210/jendso/bvab048.1727

Ejemplares similares